GlassScriptPhysician profile
Halah Al Dadah
NPI 1205043510
$8,204.92
in general payments reported to CMS, 2019-2025
34 companies · $847 in 2025
The $847 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $788 · 2021: $1,237 · 2022: $1,289 · 2023: $1,520 · 2024: $1,217 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,584.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,424.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,311.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $927.75 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $787.77 | 2019-2024 | |
| Lilly USA, LLC | $501.13 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Horizon Therapeutics Plc | $345.37 | 2019-2022 | |
| Astellas Pharma US INC | $259.46 | 2019-2023 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $258.34 | 2019-2024 | Trintellix |
| Allergan, INC. | $232.05 | 2019-2020 | |
| Amgen INC. | $211.74 | 2021-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $182.70 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $182.05 | 2019-2022 | |
| Dexcom, INC. | $172.60 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.36 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $154.80 | 2022-2025 | Rybelsus, Ozempic |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halah Al Dadah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.